nPODDDS Canadian Trademark Information

On Tuesday, July 16, 2013, a canadian trademark registration was filed for nPODDDS by Intellipharmaceutics Corp. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1635387. The current status of this trademark filing is Registration published. The nPODDDS trademark is filed in the description of Drug delivery systems, namely controlled timed release and/or targeted release pharmaceutical compositions provided as an integral component of pharmaceutical preparations; drug delivery systems, namely controlled timed released and/or targeted release pharmaceutical compositions, in the nature of oral solid dose tablets or capsules, provided as an integral component of pharmaceutical preparations; pharmaceutical preparations incorporating controlled timed release and/or targeted release pharmaceutical compositions in the nature of drug delivery systems as an integral component, all for the use in the treatment of attention deficit disorders, central nervous systems disorders, depression, diabetes, epilepsy, gastric disorders, gastro-intestinal tract disorders , hypertension, infection, inflammation, pain, rheumatoid arthritis and rhinitis. , Research and development services for others in the pharmaceutical sciences, namely, the development and application of drug delivery technologies to the development of controlled, timed release and/or targeted release pharmaceutical preparations. , Drug delivery systems, namely controlled timed release and/or targeted release pharmaceutical compositions provided as an integral component of pharmaceutical preparations; drug delivery systems, namely controlled timed released and/or targeted release pharmaceutical compositions, in the nature of oral solid dose tablets or capsules, provided as an integral component of pharmaceutical preparations; pharmaceutical preparations incorporating controlled timed release and/or targeted release pharmaceutical compositions in the nature of drug delivery systems as an integral component, all for the use in the treatment of attention deficit disorders, central nervous systems disorders, depression, diabetes, epilepsy, gastric disorders, gastro-intestinal tract disorders , hypertension, infection, inflammation, pain, rheumatoid arthritis and rhinitis. , Research and development services for others in the pharmaceutical sciences, namely, the development and application of drug delivery technologies to the development of controlled, timed release and/or targeted release pharmaceutical preparations. .